Five GCTs were mutation-negative, including the two juvenile-type GCTs . Two mutation-negative tumors didn’t communicate inhibin or calretinin, which were expressed in 100 percent and 86 percent of the mutation-positive GCTs, respectively . The fifth mutation-negative tumor experienced a prominent fibrothecomatous component, also seen in two mutation-positive samples . The FOXL2 mutation was absent in 149 additional epithelial ovarian tumors and in 180 breasts cancers . Sample GCT18, a thecoma, was the only real non-GCT tumor that was positive for the FOXL2 variant in the first validation series.To 1 1:00 p.m., [Poster No. SU0300]Romantic relationship between body composition and the skeleton Oct. 17, 11:00 a.m. To at least one 1:00 p.m., [Poster No. SU0299]Modification of the Osteoporosis Individual Evaluation Questionnaire using item response theory strategies Oct. 17, 11:00 a.m. To 1 1:00 p.m., [Poster No. SU0410]Features of a Puerto Rican population initiating teriparatide therapy in the DANCE study Oct. 18, 11:30 a.m. To at least one 1:30 p.m., [Poster No. MO0370]Attitudes toward compliance of individuals participating in a randomized managed trial Oct. 18, 11:30 a.m. To 1 1:30 p.m., [Poster No. Foster) Oct. 18, 11:30 a.m. To at least one 1:30 p.m., [Poster No.